UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 539

Sortiert nach

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Journal of medicinal chemistry, 2020-07, Vol.63 (14), p.7510-7528

2020

Volltextzugriff (PDF)

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.941-964

2019

Volltextzugriff (PDF)

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Journal of medicinal chemistry, 2019-01, Vol.62 (2), p.448-466

2019

Volltextzugriff (PDF)

Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors

Scientific reports, 2020-05, Vol.10 (1), p.7399-7399, Article 7399

Yang, Chao-Yie

2020

Volltextzugriff (PDF)

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Journal of medicinal chemistry, 2018-08, Vol.61 (15), p.6685-6704

2018

Volltextzugriff (PDF)

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Nature communications, 2021-05, Vol.12 (1), p.2621-2621, Article 2621

2021

Volltextzugriff (PDF)

Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method

PloS one, 2015-02, Vol.10 (2), p.e0118671-e0118671

2015

Volltextzugriff (PDF)

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Journal of medicinal chemistry, 2019-12, Vol.62 (24), p.11280-11300

2019

Volltextzugriff (PDF)

MCL-1 inhibition in cancer treatment

OncoTargets and therapy, 2018-01, Vol.11, p.7301-7314

2018

Volltextzugriff (PDF)

Risk factors of asthma in the Asian population: a systematic review and meta-analysis

Journal of physiological anthropology, 2021-12, Vol.40 (1), p.22-22, Article 22

2021

Volltextzugriff (PDF)

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

Cancer research (Chicago, Ill.), 2017-05, Vol.77 (9), p.2476-2487

2017

Volltextzugriff (PDF)

The Making of I‑BET762, a BET Bromodomain Inhibitor Now in Clinical Development

Journal of medicinal chemistry, 2013-10, Vol.56 (19), p.7498-7500

2013

Volltextzugriff (PDF)

Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study

The European respiratory journal, 2018-07, Vol.52 (1), p.1800766-1800766

2018

Volltextzugriff (PDF)

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

Nature communications, 2017-10, Vol.8 (1), p.1150-12, Article 1150

2017

Volltextzugriff (PDF)

The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response

Genes & development, 2013-08, Vol.27 (16), p.1752-1768

2013

Volltextzugriff (PDF)

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Journal of medicinal chemistry, 2011-04, Vol.54 (8), p.2714-2726

2011

Volltextzugriff (PDF)

Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)

Journal of medicinal chemistry, 2017-03, Vol.60 (6), p.2212-2214

2017

Volltextzugriff (PDF)

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein–Protein Interaction

Journal of medicinal chemistry, 2018-03, Vol.61 (5), p.1934-1950

2018

Volltextzugriff (PDF)

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Blood, 2021-12, Vol.138 (26), p.2781-2798

2021

Volltextzugriff (PDF)

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Journal of medicinal chemistry, 2020-10, Vol.63 (20), p.11368-11396

2020

Volltextzugriff (PDF)

The PDBbind Database: Methodologies and Updates

Journal of medicinal chemistry, 2005-06, Vol.48 (12), p.4111-4119

2005

Volltextzugriff (PDF)

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development

Journal of medicinal chemistry, 2020-07, Vol.63 (13), p.7252-7267

2020

Volltextzugriff (PDF)

Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein−Ligand Complexes

Journal of chemical information and modeling, 2007-03, Vol.47 (2), p.668-675

2007

Volltextzugriff (PDF)

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression

Journal of medicinal chemistry, 2021-10, Vol.64 (19), p.14540-14556

2021

Volltextzugriff (PDF)

Functional variants in the chromosome 4q21 locus contribute to allergic rhinitis risk by modulating the expression of N‐acylethanolamine acid amidase

Clinical and experimental allergy, 2022-01, Vol.52 (1), p.127-136

2022

Volltextzugriff (PDF)

1 – 25 von 539

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(355)
Mit Volltextzugriff
(498)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer

Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression

Comparative Analyses of the Conformational Dynamics Between the Soluble and Membrane-Bound Cytokine Receptors

Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression

Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity

Identification of potential small molecule allosteric modulator sites on IL-1R1 ectodomain using accelerated conformational sampling method

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

MCL-1 inhibition in cancer treatment

Risk factors of asthma in the Asian population: a systematic review and meta-analysis

Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer

The Making of I‑BET762, a BET Bromodomain Inhibitor Now in Clinical Development

Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study

A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation

The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response

A Potent and Orally Active Antagonist (SM-406/AT-406) of Multiple Inhibitor of Apoptosis Proteins (IAPs) in Clinical Development for Cancer Treatment

Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED)

High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein–Protein Interaction

The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

The PDBbind Database: Methodologies and Updates

EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development

Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein−Ligand Complexes

Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression

Functional variants in the chromosome 4q21 locus contribute to allergic rhinitis risk by modulating the expression of N‐acylethanolamine acid amidase

Suchergebnisse filtern